




a global oncology company with a proprietary platform

Novocure is a global oncology company developing a proprietary platform technology called Tumor Treating Fields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure also has a growing commercial business with its lead product, Optune, which is currently approved for the treatment of adult patients with glioblastoma. Novocure has significant upside potential with ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.

we can leverage physics to fight cancer



growing commercial business




8000+

ACTIVE PATIENTS CURRENTLY ON THERAPY

\$217

MILLION TRAILING TWELVE MONTH REVENUES

ACTIVE PATIENTS AT PERIOD END



● U.S. active patients ● EMEA Active patients ● Japan active patients


GLOBAL ACTIVE MARKETS AS OF JUNE 30, 2018



| | U.S. | EMEA | JAPAN |
|-----------------------|-------|-------|-------|
| eligible patient pop. | 9,300 | 3,450 | 1,100 |
| estimated penetration | 30% | 20% | 10% |

● active markets

an advancing clinical pipeline in multiple solid tumors



pre-clinical data for tumor treating fields also in these areas


- Ependymoma
- Medulloblastoma
- Meningioma
- Small cell lung cancer
- Renal cell adenocarcinoma
- Cervical cancer
- Colorectal carcinoma
- Gastric adenocarcinoma
- Urinary transitional cell carcinoma
- Breast cancer
- Malignant melanoma

at-a-glance overview

FOUNDED: 2000
 IPO: OCTOBER 2, 2015
 TICKER: NVCR (NASDAQ)
 MARKET CAP (AS OF 6/30/2018): \$2.8 BILLION
 NUMBER OF EMPLOYEES: 450+
 2017 NET REVENUES: \$177.0 MILLION
 HEADQUARTERS: JERSEY ISLE

demonstrated financial performance

GLOBAL NET REVENUES (USD IN THOUSANDS)



60%
 YEAR-OVER-YEAR REVENUE GROWTH Q2 2018 VS. Q2 2017

\$219
 MILLION IN CASH AND SHORT-TERM EQUIVALENTS AS OF JUNE 30, 2018

● U.S. net revenues ● EMEA net revenues ● Japan net revenues

executive leadership

- WILLIAM F. DOYLE
Executive Chairman
- ASAF DANZIGER
Chief Executive Officer
- MIKE AMBROGI
Chief Operating Officer
- WILCO GROENHUYSEN
Chief Financial Officer
- EILON KIRSON, M.D., PH.D.
Chief Science Officer
- TODD LONGSWORTH
General Counsel
- PRITESH SHAH
Chief Commercial Officer
- YORAM PALT, M.D., PH.D.
Founder

contact information

MEDIA AND INVESTORS
 Ashley Cordova
 Vice President, Finance & Investor Relations
 212-767-7558
 investorinfo@novocure.com